Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 21
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Redhill Biopharma Ltd
RDHL
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$0.5073
0.0061
1.22%
Ult. Agg.: Oct 20, 4:17 PM
$0.5174
0.0162
3.23%
Get Report
Panoramica
Notizie
Previsioni utili
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Privacy Manager
Redhill Biopharma Financials
Redhill Biopharma (RDHL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Redhill Biopharma H1 2026 EPS $0.00 And Revenue $0.00
Redhill Biopharma (NASDAQ:RDHL) reported H1 2026 EPS $0.00 And Revenue $0.00.
Benzinga Newsdesk
PRO
Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY
Redhill Biopharma (NASDAQ:RDHL) reported quarterly earnings of $0.00 per share. The company reported $286.000 thousand in sales this quarter. This is a 96.44 percent decrease over sales of $8.043 million the same period
Benzinga Newsdesk
PRO
Redhill Biopharma H1 Sales $4.079M Up From $2.572M YoY
Redhill Biopharma (NASDAQ:RDHL) reported $4.079 million in sales this quarter. This is a 58.59 percent increase over sales of $2.572 million the same period last year.
Benzinga Newsdesk
PRO
Redhill Biopharma FY 2024 EPS $(0.00) Down From $0.01 YoY, Sales $8.04M Up From $6.53M YoY
Redhill Biopharma (NASDAQ:RDHL) reported quarterly losses of $(0.02) per share. This is a 300 percent decrease over earnings of $0.01 per share from the same period last year. The company reported $8.04 million in sales
Benzinga Newsdesk
PRO
Redhill Biopharma H1 EPS $(0.00) Down From $0.04 YoY, Sales $2.57M Down From $5.39M YoY
Benzinga Newsdesk
Crude Oil Moves Lower; Moderna Shares Plunge
Avi Kapoor
